Abiomed's Impella(R) Technology Showcased at TCT 2013 With Over 25 Accepted Presentations in the Scientific Sessions

Wed Oct 23, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

DANVERS, Mass., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, notes that there will be over 25 potential Impella presentations in the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific meeting, scheduled from October 27 – November 1, at the Moscone Convention Center in San Francisco, CA.

On the TCT show floor, Abiomed will conduct daily booth demonstrations at Abiomed booth #1307 and hands-on simulations of the Impella platform.

For further information about the TCT scientific program and the timing of scientific presentations, please contact Aimee Genzler, Corporate Communications Manager, at agenzler@abiomed.com or 978-646-1553.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

CONTACT: For further information please contact:
         Aimee Genzler
         Corporate Communications Manager
         978-646-1553
         agenzler@abiomed.com
         
         Susie Lisa
         Senior Director, Investor Relations, Corporate Development
         978-646-1590
         slisa@abiomed.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.